Cost-effectiveness of the addition of sintilimab as a first-line therapy for locally advanced or metastatic oesophageal squamous cell carcinoma: a Chinese healthcare system perspective
In patients with locally advanced or metastatic OSCC, sintilimab chemotherapy could improve survival time and health benefits compared with traditional chemotherapy, but the present analysis suggests that sintilimab is not a cost-effective treatment option in China.
Authors
- Hui Yan (ORCID: https://orcid.org/0000-0002-6990-2526)
- Yadi Geng
- Ji Peng (ORCID: https://orcid.org/0000-0002-4677-092X)
- Cuicui Yu (ORCID: https://orcid.org/0000-0003-0819-0032)
- Pengli Zhu (ORCID: https://orcid.org/0000-0001-6830-7760)
- Lijuan Ning
- Yubin Feng
- Fei Wu (ORCID: https://orcid.org/0000-0001-5974-4029)
- Aizong Shen (ORCID: https://orcid.org/0000-0001-9009-6410)
- Yingqi Wu (ORCID: https://orcid.org/0000-0002-6068-0066)
Institutions
- University of Science and Technology of China (CN)
- Hefei Material Science and Technology Center (CN)
Publication Details
- Journal
- Health Economics Review
- Published
- 2025-01-10
- DOI
- https://doi.org/10.1186/s13561-024-00588-2
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China